Abstract
CODE therapy demonstrated high antitumor activity in extensive-stage small cell lung cancer (SCLC). Toxicity was acceptable in a regimen with a nine-cycle schedule. The results obtained in this study suggest that CODE therapy improves the outcome of patients with extensive-stage SCLC. The use of recombinant human granulocyte colony-stimulating factor may well reduce the duration and degree of neutropenia during CODE chemotherapy and increase the dose intensity, leading to further improvement of outcome.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / blood
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / pathology
-
Cisplatin / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Follow-Up Studies
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Hemoglobins / metabolism
-
Humans
-
Lung Neoplasms / blood
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Recombinant Proteins / therapeutic use
-
Time Factors
-
Treatment Outcome
-
Vincristine / administration & dosage
Substances
-
Hemoglobins
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cisplatin